SLC25A26

Across TCGA pan-cancer cohorts, SLC25A26 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC25A26’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC25A26 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC25A26 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where SLC25A26 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A26 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.836	<.001	11	view →
PDAC	All	All	+0.877	<.001	6	view →
HNSC	All	All	−0.284	.001	6	view →
COAD	Male	III,IV	+0.917	.033	1	view →
LSCC	Female	III,IV	−0.423	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLC25A26–CCRCC

Open the CCRCC breakdown →